Accessibility came up again and again during the hearing, largely because the FDA listed a requirement in a July guidance that if the lead monitor of a psychedelic dosing session is not a physician, ...

Cellectis is also switching over to in vivo, channelling its resources to two preclinical candidates: HEAL-101, an in vivo ...

With Novo axing monlunabant, Corbus has a chance to establish CRB-913 as the frontrunner in the CB1 race. The phase 1b data ...

Electra Therapeutics is hoping to raise up to $341.9 million in a surge of IPO funding to power the clinical development of its inflammatory disorder drug ipsoprubart. | Electra Therapeutics is hoping ...

Eli Lilly has put the kibosh on an early-stage obesity drug after the candidate didn’t meet the pharma giant’s lofty expectations. | Eli Lilly has put the kibosh on an early-stage obesity drug after ...

BioNTech has linked gotistobart to median overall survival (OS) of 18.5 months in relapsed lung cancer patients, adding to evidence that the anti-CTLA-4 antibody is better than the standard of care.

MediLink has reported phase 3 results on a Roche-partnered antibody-drug conjugate (ADC). The small cell lung cancer (SCLC) trial hit its primary endpoint, although the B7-H3-dire ...